Mer­ck cel­e­brates an­oth­er win in Janu­via patent bat­tle against Vi­a­tris

Vi­a­tris has suf­fered its sec­ond sting­ing loss in as many weeks in its at­tempt to chal­lenge Mer­ck’s Janu­via and Janu­met patents.

A fed­er­al ap­peals court on Thurs­day up­held Mer­ck’s patent rights re­lat­ed to the di­hy­dro­gen phos­phate salt of sitagliptin — an ac­tive in­gre­di­ent in the block­buster di­a­betes drugs Janu­via, Janu­met and ex­tend­ed-re­lease for­mu­la­tion Janu­met XR — call­ing Vi­a­tris’ claims “un­per­sua­sive.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER